Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Juni 2024 08:20 ET | Quelle: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses...
17. August 2023 08:05 ET | Quelle: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER,...
13. Dezember 2022 02:00 ET | Quelle: QUADIENT

Quadient annonce qu’un quatrième transporteur rejoint son réseau ouvert de consignes colis au Royaume-Uni

Quadient annonce qu’un quatrième transporteur rejoint son réseau ouvert de consignes colis au Royaume-Uni Paris, le 13 décembre 2022 Quadient (Euronext Paris : QDT), un opérateur majeur de consignes...
13. Dezember 2022 02:00 ET | Quelle: QUADIENT

Quadient Announces Fourth Carrier Joining its Smart Locker Open Network in the UK

Quadient Announces Fourth Carrier Joining its Smart Locker Open Network in the UK Paris, December 13, 2022 Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer...
20. April 2022 08:30 ET | Quelle: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine)

Processa focuses on identifying the PCS6422 regimens to increase capecitabine potency while identifying the MTD of Next Generation Capecitabine The amended protocol will provide a more precise...